Cleveland Clinic is dedicated to being a leader in patient experience, clinical outcomes, research, and education for patients with amyloidosis. Specialists in our Cancer Center and Sydell and Arnold Miller Family Heart & Vascular Institute work together to provide the most advanced treatment options for patients with amyloidosis. Our heart care is ranked No. 1 in the country by U.S. News & World Report. Our cancer program is top-ranked in Ohio and No. 5 in the country according to the same survey.
A Team Approach
Depending on the symptoms and type of amyloidosis, there will be different specialty doctors involved. The initial evaluation will be done by one of our amyloid specialists in cardiology or cancer care, with possible additional involvement of specialists in neurology, nephrology, gastroenterology, hematology/oncology, genetics and primary care. Together, our amyloid specialists explore all options and tailor the most appropriate treatment plan for each patient, taking into consideration your goals and quality of life. Each patient will also have a patient care coordinator to help coordinate appointments with the various specialists involved. The Amyloidosis Center is led by co-directors Jason Valent, MD, from Hematology and Medical Oncology, and Mazen Hanna, MD, from Cardiovascular Medicine.
What We Treat
Amyloidosis (am-uh-loy-doh-sis) is a protein disorder. In this disease, proteins change shape (misfold), then clump together and form amyloid fibrils which deposit in organs. As amyloid fibrils build up, the tissues and organs may not work as well as they should.
Our bodies make several proteins that can cause amyloidosis. To choose the right treatment, it is very important to know the exact protein that is causing the disease. The two most common types are light chain (AL) and transthyretin (ATTR) amyloidosis.
Find more information in our Health Library related to Amyloidosis.
Support & Services
In addition to offering state of the art diagnostic techniques and amyloidosis treatments, our specialists also offer an array of resources that can help patients cope with the demands of a chronic disease.
- Learn more about our Cancer Center resources
- Learn more about our Heart and Vascular Institute resources
Additional External Resources
Clinical Trials & Research
Generous philanthropic donations have enabled the creation of the Cleveland Clinic Term Chair in Amyloid Heart Disease, which has helped fund numerous studies and allowed for the creation of a dedicated research fellow position to further our work in the field. The Cleveland Clinic Amyloidosis Center has participated in all of the major multi-center treatment trials in AL and ATTR amyloidosis, and readily collaborates with the national and international amyloidosis community to promote advancements in therapies and our understanding of the disease.
Clinical trials of new treatments are available for patients with amyloidosis. Our team at Cleveland Clinic is a leader in research efforts to develop diagnosis and treatment strategies to improve our patients’ outcomes. Cleveland Clinic offers several clinical trials for patients with amyloidosis. If your Cleveland Clinic amyloidosis specialist feels you might benefit from participating in a clinical trial, the options will be discussed with you in detail.
Current and Upcoming Trials
- MED-hATTR: Monitoring of Early Disease Progression in Hereditary ATTR Amyloidosis (hereditary ATTR) – NCT03431896
- The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis (AL & ATTR) – NCT03040427
- Inotersen Expanded Access Program (ATTR) – NCT03400098
- CyBorD +/- Daratumumab in Newly Diagnosed AL Amyloidosis (AL) – NCT03201965
- Dexamethasone + Ixazomib in Relapsed or Refractory AL Amyloidosis (AL) – NCT01659658
- Anti-SAP Treatment Study (AL & ATTR) – NCT03044353
Ongoing Trial, Closed to Recruitment
- ATTR-ACT: Safety and Efficacy of Tafamidis in Patients with ATTR Cardiomyopathy (ATTR) – NCT01994889
- The PRONTO Study: NEOD001 in AL Amyloidosis (AL) – NCT02632786
- The VITAL Study: NEOD001 in AL Amyloidosis (AL) – NCT02312206
- Melphalan and Dexamethasone +/- Bortezomib in Previously Untreated AL Amyloidosis (AL) – NCT01078454
- High-Dose Melphalan and Autologous Peripheral Stem Cell Transplant in Patients with Multiple Myeloma or AL Amyloidosis (AL) – NCT00064337
- Revusiran in Patients with ATTR Cardiac Amyloidosis (ATTR) – NCT01981837
- ENDEAVOR: Revusiran in ATTR-Mediated Familial Amyloidotic Cardiomyopathy (ATTR) – NCT02319005
Cleveland Clinic is committed to working with you to provide the best care for your patients. Our team is also dedicated to the training and education of medical professionals to advance care and research of amyloidosis.
To refer a patient, please contact our Referring Physician Hotline, available 24 hours a day, 7 days a week, for all your needs, by calling 855.REFER.123 (855.733.3712).